The US House Select Committee on China has launched an investigation into drugmakers Merck and AbbVie over clinical trials conducted at Chinese military hospitals and facilities in Xinjiang. Lawmakers are demanding transparency regarding data protection and participant consent, citing severe national security and human rights concerns within the biopharma sector.
WASHINGTON, D.C. — A prominent bipartisan U.S. congressional panel has launched a sweeping national security and ethical investigation into whether American pharmaceutical giants Merck & Co. and AbbVie Inc. have engaged in clinical trials within China that inadvertently advanced the country's military research capabilities. In formal letters issued to the chief executives of both firms, the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party demanded comprehensive transparency regarding their operations at Chinese medical facilities, particularly those linked to the People’s Liberation Army (PLA) and sites located in the heavily repressed Xinjiang region.
The expanding probe highlights intensifying federal scrutiny over the global biotechnology supply chain. It marks a critical escalation in Washington’s efforts to decouple sensitive medical technology and data from Beijing, amid concerns that American intellectual property and patient resources are being leveraged by a strategic adversary.
Allegations of Ethical Violations and Intellectual Property Theft
The congressional inquiry, led by Representative John Moolenaar, a Republican from Michigan and Chairman of the House Select Committee on China, details multiple areas of severe compliance risk. Bipartisan lawmakers expressed deep anxiety that early-stage human drug trials conducted in Chinese military hospitals subject proprietary American biopharmaceutical data to China’s sweeping National Security Law, which legally compels organizations to share information with state intelligence services.
Furthermore, the committee raised serious humanitarian concerns regarding clinical trial sites operating within the Xinjiang Uyghur Autonomous Region (XUAR). Lawmakers noted that Xinjiang remains the global epicenter of state-sponsored human rights abuses and forced assimilation targeting Uyghurs and other ethnic minorities.
The committee explicitly questioned whether trial participants in these zones are capable of providing true, uncoerced informed consent, given the pervasive environment of state surveillance and detention.
Major Areas of Congressional Inquiry
PLA Hospital Affiliations: Identifying every clinical trial conducted alongside or within medical centers operated by the People’s Liberation Army.
Xinjiang Operational Oversight: Reviewing the ethical verification mechanisms used to ensure ethnic minorities are not forced into experimental drug programs.
Intellectual Property Protection: Examining the data security frameworks preventing the involuntary transfer of advanced genetic or molecular technology to Chinese state labs.
Global Shift in Clinical Trial Infrastructure
The investigation unfolds against a profound structural shift in global drug development. Over the past decade, regulatory adjustments, extensive state subsidies, and lowered compliance costs have allowed China to outstrip western nations in early-stage pharmaceutical testing volume.
Industry data presented during recent congressional hearings indicates that between 2015 and 2026, the United States' share of global early-stage drug development programs declined from 48% to roughly 37%. Concurrently, China’s global share surged from 8% to over 32%, positioning the nation as a dominant force in oncology and specialized biopharma research.
Official Sources Section
The opening of the investigation was confirmed via official oversight correspondence drafted by the House Select Committee on China. Similar inquiries were simultaneously extended to other multinational pharmaceutical operators, including Pfizer Inc. and Bristol Myers Squibb, indicating an industry-wide review.
When contacted for comment following the public disclosure of the congressional letters, a spokesperson for Merck stated that patient safety and absolute ethical integrity remain the core priorities of its international clinical research programs, asserting that the company strictly adheres to all global regulatory guidelines. Conversely, representatives for AbbVie declined to comment on the ongoing congressional matter.
A diplomatic representative for the Chinese Embassy in Washington, D.C., forcefully rejected the premise of the probe in an emailed statement, claiming that:
"There is nothing credible in the committee's actions. China remains firmly opposed to any unilateral moves aimed at politicizing commercial trade, corporate investments, and standard technological collaboration."
The committee has mandated that both Merck and AbbVie provide detailed disclosures regarding their corporate due diligence, data protection processes, and historical trial site profiles in China by July 17, 2026.
Why It Matters
For everyday consumers, patients, and healthcare investors, the outcome of this probe carries significant weight. If Congress imposes strict statutory bans or licensing mandates on conducting clinical trials in Chinese facilities, American drugmakers will face ballooning drug development costs and prolonged trial timelines as they scramble to reshore clinical testing infrastructure. However, failure to secure these supply chains risks giving foreign entities access to sensitive genetic data and the foundational building blocks of next-generation therapies, potentially compromising U.S. health security during a future geopolitical crisis.
Key Facts at a Glance
Investigation Target: Bipartisan House inquiry into Merck and AbbVie regarding clinical trial sites in China.
Key Risk Vectors: Operational footprints inside PLA military hospitals and the Xinjiang region.
Compliance Deadline: Both pharmaceutical companies must surrender internal due diligence and data logs by July 17, 2026.
Underlying Trend: China’s share of global early-stage drug development has skyrocketed to over 32% since 2015.
Frequently Asked Questions (FAQ)
Why are U.S. drug trials conducted in China in the first place?
China offers a vast patient pool, significantly lower operational costs, and streamlined regulatory approvals. This allows multinational companies to complete early-stage human drug testing much faster than is typically possible in Western nations.
Are Merck and AbbVie accused of breaking U.S. laws?
No. The House Select Committee on China explicitly clarified that there is currently no direct evidence that the companies have engaged in illegal activities. The probe is an oversight and risk-assessment initiative focusing on national security and ethical vulnerabilities.
What are the potential consequences if violations are uncovered?
If the inquiry uncovers systemic ethical failures or intellectual property leakage, Congress could draft legislation under the Biosecurity Act framework. This could deny such drugs FDA approval, restrict federal funding, or impose severe sanctions on companies collaborating with blacklisted foreign military institutions.
Source: * House Select Committee on the CCP Official Archive
